Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Friday after HC Wainwright raised their price target on the stock from $21.00 to $22.00. HC Wainwright currently has a buy rating on the stock. Aura Biosciences traded as high as $12.38 and last traded at $11.82, with a volume of 585739 shares traded. The stock had previously closed at $10.29.
Several other research firms have also issued reports on AURA. JMP Securities lifted their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a report on Friday, September 13th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Aura Biosciences currently has a consensus rating of “Buy” and an average target price of $22.00.
View Our Latest Report on AURA
Insider Transactions at Aura Biosciences
Hedge Funds Weigh In On Aura Biosciences
Institutional investors and hedge funds have recently modified their holdings of the business. Regency Capital Management Inc. DE increased its position in shares of Aura Biosciences by 11.4% in the first quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock valued at $6,163,000 after buying an additional 80,162 shares in the last quarter. American International Group Inc. lifted its position in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares in the last quarter. Levin Capital Strategies L.P. grew its holdings in shares of Aura Biosciences by 11.2% during the first quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company’s stock worth $873,000 after buying an additional 11,200 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Aura Biosciences in the first quarter valued at about $144,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Aura Biosciences by 51.4% in the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after buying an additional 48,549 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.
Aura Biosciences Trading Up 13.5 %
The stock’s fifty day simple moving average is $8.59 and its 200 day simple moving average is $8.03. The company has a market cap of $578.66 million, a price-to-earnings ratio of -5.53 and a beta of 0.37.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.04. On average, analysts predict that Aura Biosciences, Inc. will post -1.7 EPS for the current year.
About Aura Biosciences
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Featured Stories
- Five stocks we like better than Aura Biosciences
- Investing in Travel Stocks Benefits
- Analysts See Growth in CrowdStrike Stock Despite July Setback
- How Technical Indicators Can Help You Find Oversold StocksĀ
- The Uptrend in Netflix Will Continue: Another 15% Upside Ahead
- What Are Dividend Challengers?
- Buy the Dip? UiPath Stock’s GenAI Strategy May Pay Off
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.